The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...

S&P500 holds flat as traders eye Fed’s rate decision, strong GDP data, and Big Tech earnings. Market sentiment hinges on ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

Volatility: Blue chip stocks are usually less volatile than other stocks.

Pfizer Inc. (NYSE: PFE) delivered a stronger-than-anticipated second-quarter performance, beating analyst estimates and ...

Pfizer Inc. (NYSE: PFE) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 5, the ...

Q2 2025 Earnings Call Transcript August 6, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.83836, ...

At first glance, Pfizer delivered a strong Q2 and upped its 2025 full-year EPS guidance. Click here to find out why I rate ...

Trump Media shares dipped after launching its AI-powered Truth Search beta with Perplexity, even as the company reported $3.1 ...

While Pfizer remains on track for an impressive $7.2 billion in cost cuts by the end of 2027, we think the market is more ...

Pfizer Inc displayed a robust performance in its Q2 2025 earnings call, with significant strides in revenue and research ...

Central to Nxera’s pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from ...